Novo Nordisk Reports About 21% Weight Loss With Lower CagriSema Doses
Novo Nordisk on November 14, 2026 reported detailed REDEFINE 9 results showing estimated mean weight loss of 20.7% with CagriSema 1.7 mg/1.7 mg and 21.0% with 1.0 mg/1.0 mg at 68 weeks, compared with 2.0% with placebo. The figures, in adults with overweight or obesity, use the efficacy estimand, which estimates the treatment effect if all participants adhered to treatment. The phase 3b data were presented at ObesityWeek 2026 in Washington and published simultaneously in The Lancet Diabetes &…